Drug information of Aducanumab and its effectiveness for Alzheimer’s disease: A clinical review
1 Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat.
2 Dept. of Pharmacy Practice, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat.
3 Prof. and Principal, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat.
Review
International Journal of Biological and Pharmaceutical Sciences Archive, 2021, 02(02), 072–077.
Article DOI: 10.53771/ijbpsa.2021.2.2.0094
Publication history:
Received on 27 October 2021; revised on 20 December 2021; accepted on 22 December 2021
Abstract:
Alzheimer’s disease (AD) is the main cause of disability in people older than 60 years. More than 1 million cases per year reported in India. AD and other kinds of dementia are more common as individuals become older, affecting 1 in every 14 people over the age of 65 and 1 in every 6 people over the age of 80. ADUHELM (Aducanumab) is a monoclonal antibody, new class of medication needed for treatment of AD. The latest drug used to treat underlying cause of AD and recent studies shown to be efficacious and safe for the AD. Our review emphasizes on the drug information of Aducanumab and its clinical importance in AD.
Keywords:
Alzheimer’s disease; Aducanumab; Drug information; Genetic mutations.
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0